派林生物(000403.SZ)：人凝血酶获得药品注册临床试验受理通知书

Core Viewpoint - The company, Palin Bio (000403.SZ), announced that its wholly-owned subsidiary, Guangdong Shuanglin Biopharmaceutical Co., Ltd., has received the clinical trial acceptance notice for human thrombin drug registration from the National Medical Products Administration [1] Group 1 - The human thrombin is indicated for external use only, aimed at controlling minor bleeding from capillaries and small veins when standard surgical techniques are ineffective or impractical [1] - The product can be used in conjunction with absorbable gelatin sponges [1]